Found: 6
Select item for more details and to access through your institution.
Semaglutide improves health‐related quality of life versus placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 8, p. 1339, doi. 10.1111/dom.14039
- By:
- Publication type:
- Article
The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
- Published in:
- Diabetes, Obesity & Metabolism, 2020, v. 22, n. 5, p. 779, doi. 10.1111/dom.13954
- By:
- Publication type:
- Article
2187-PUB: Identifying Risk Predictors for Gastrointestinal Adverse Events with Once-Weekly Semaglutide.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-2187-PUB
- By:
- Publication type:
- Article
2160-PUB: Development of an Evidence-Based Tool to Facilitate Individualized Treatment in the Clinic for Patients with Type 2 Diabetes.
- Published in:
- Diabetes, 2020, v. 69, p. N.PAG, doi. 10.2337/db20-2160-PUB
- By:
- Publication type:
- Article
1003-P: Clinical Response (HbA<sub>1c</sub> ≥1% and/or Body Weight ≥5% Reduction) to Semaglutide by Baseline HbA<sub>1c</sub> and Body Weight in the SUSTAIN Program.
- Published in:
- Diabetes, 2019, v. 68, p. N.PAG, doi. 10.2337/db19-1003-P
- By:
- Publication type:
- Article
Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young.
- Published in:
- European Journal of Endocrinology, 2015, v. 173, n. 2, p. 205, doi. 10.1530/EJE-15-0070
- By:
- Publication type:
- Article